Kimmo Porthan

Distinct effects of ketogenic and non-ketogenic weight-loss diets on hepatic steatosis and mitochondrial metabolism in MASLD

Sami F. Qadri, Kimmo Porthan, Sylvie Dufour, Tiina E. Lehtimäki et autres

BACKGROUND & AIMS: Weight loss is the cornerstone of therapy for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the optimal dietary approach for reducing intrahepatic triglycerides (IHTG) and the mechanisms underlying steatosis resolution remain poorly defined. We investigated whether weight loss via …

fi, us (code pays fourni par la source)

Hepatic insulin resistance is the basis of bile acid dysmetabolism in metabolic dysfunction-associated steatotic liver disease

S. U. Qadri, Joel T. Haas, Sirkku Jäntti, Kimmo Porthan et autres

Summary Bile acids (BAs) are liver-synthesized steroids that facilitate lipid digestion and regulate diverse metabolic pathways. Because of their cytotoxicity, excessive hepatic BA accumulation has been implicated in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). Although circulating BAs are frequently …

fi, fr, be, se (code pays fourni par la source)

THU-452-YI Intravenous infusions of fatty acids and ethanol induce hepatic mitochondrial reductive stress in humans

Kimmo Porthan, Sirkku Jäntti, Mari J. Jokinen, Anni I. Nieminen et autres

OS-084-YI HSD17B13 loss-of-function protects against steatosis-induced hepatic phosphatidylcholine depletion by promoting polyunsaturated fatty acid retention in humans in vivo and in experimental models

Leanne Hodson, Kimmo Porthan, Anne Juuti, Anne Penttilä et autres

OS-014-YI Bariatric surgery identifies a protective amino acid in metabolic dysfunction-associated steatotic liver disease

Laura Granö, Juho Asteljoki, Nova Hongisto, Kimmo Porthan et autres

HEART RATE VARIABILITY AND BAROREFLEX SENSITIVITY AS PREDICTORS OF ANTIHYPERTENSIVE DRUG RESPONSES

Heini Sánez Tähtisalo, Juha Virolainen, Kimmo Porthan, Kimmo Kontula et autres

Objective: Treatment goals in hypertension are not often met, while essential hypertension remains the leading risk factor of global disease burden. We studied whether blood pressure (BP) responses to four antihypertensive monotherapies are associated with baseline heart rate variability (HRV) and baroreflex …

fi (code pays fourni par la source)

Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD

Yasaman Vali, Anne‐Marieke van Dijk, Jenny Lee, Jérôme Boursier et autres

BACKGROUND AND AIMS: The performance of non-invasive liver tests (NITs) is known to vary across settings and subgroups. We systematically evaluated whether the performance of three NITs in detecting advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) varies with …

nl, fr, us, de, it, es, gb, fi, se, be (code pays fourni par la source)

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder, Fiona Oakley et autres

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease …

gb, it, dk, de, us, ch, se, lu, pt, jp, fr, gr, be, es (code pays fourni par la source)

The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans

Panu K. Luukkonen, Kimmo Porthan, Noora Ahlholm, Fredrik Rosqvist et autres

The PNPLA3 I148M variant is the major genetic risk factor for all stages of fatty liver disease, but the underlying pathophysiology remains unclear. We studied the effect of this variant on hepatic metabolism in homozygous carriers and non-carriers under multiple physiological conditions …

fi, us, se, gb (code pays fourni par la source)

Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis

S. U. Qadri, Emilia Vartiainen, Mari Lahelma, Kimmo Porthan et autres

Background & Aims: Pathologists quantify liver steatosis as the fraction of lipid droplet-containing hepatocytes out of all hepatocytes, whereas the magnetic resonance-determined proton density fat fraction (PDFF) reflects the tissue triacylglycerol concentration. We investigated the linearity, agreement, and correspondence thresholds between histological …

fi, ca, tr, nl, gb, us (code pays fourni par la source)

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

Michael Pavlides, Ferenc E. Mózes, Salma Akhtar, Kristy Wonders et autres

Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small proportion of those with NAFLD will develop progressive liver disease, for which …

gb, es, fr, se, it, us, de, ch, gr, fi, nl (code pays fourni par la source)

Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study

Daniel Q. Huang, Noora Ahlholm, Panu K. Luukkonen, Kimmo Porthan et autres

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD)-related fibrosis is heritable, but it is unclear how family history may be used to identify first-degree relatives with advanced fibrosis. We aimed to develop and validate a simple risk score to identify first-degree relatives …

sg, us, fi (code pays fourni par la source)